Search results for: 'airport security solutions global 2014 2014'

This Frost Radar benchmarks companies offering lab automation and monitoring solutions for diagnostics labs: hospital and independent labs including multi-chain organized, unorganized, and university labs. Lab automation solutions cover aspects of operations such as pre-pre-analytical, pre-analytical, and post-analytical workflows, whereas lab...

The COVID-19 pandemic prompted a transformation in the infectious disease point-of-care testing (POCT) market. The shift towards miniaturized POCT devices will lead to the emergence of cost-effective integrated lab-on-a-chip devices based on microfluidic technologies and smartphone-based solutions enabling multiplexed detection of infectious pathog...

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and translation of blood-based neurology biomarkers, sustai...

New technological advances in life science instrumentation and research tools include the enhancement of next-generation sequencing (NGS) technology, digital PCR, and a wide range of informatics, robotics, and automated solutions. These improve workflow, facilitate and automate tasks, and make better use of workspaces in every area of industry. ...

20 Jan 2025  |  Global  |  Market Research

Global Cardiac Biomarkers Diagnostics Industry, 2024-2029

Rising Prevalence of CVD and High Sensitivity POCT Driving Transformational Growth in Cardiac Biomarkers Diagnostics

Infographics

×

The global cardiac biomarkers diagnostics market is forecast to record robust growth with the increased prevalence of cardiovascular disease (CVD), multiplex biomarkers, advancements in diagnostic testing technology, higher POCT adoption rates, and an intensive focus on preventive healthcare. CVDs are a leading cause of mortality globally, highligh...

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...

he global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies...

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

As COVID-19 transitions to the endemic phase, automation solutions and smart, connected laboratories will catalyze recovery in the next-generation diagnostics industry. The COVID-19 pandemic left a lot of installed capacity in laboratories and healthcare centers. To take advantage of this situation, it is necessary for industry players to focus on ...